Macugen Approval Awaits CMC Review; Committee Supports Efficacy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The final decision on Pfizer/Eyetech’s Macugen awaits review of the chemistry and manufacturing sections of the NDA, FDA said during the Dermatologic & Ophthalmic Drug Products Advisory Committee’s Aug. 27 review of the clinical data.
You may also be interested in...
FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003
FDA’s efforts to increase first-cycle approvals appear to be paying off, with the agency showing a significant improvement in 2003 compared to 2002.